Environmental

VSTM’s very high R&D intensity versus revenue indicates a science-led model, but peer-relative environmental benefits are limited because the metric does not directly reduce operational footprint.

The company’s capital allocation is more research-heavy than many commercial-stage peers, yet the absence of disclosed emissions or resource-use data constrains evidence of superior environmental management.

Low leverage can support longer-dated sustainability investments, but compared with peers it is a financing attribute rather than a direct environmental differentiator.

No provided metrics indicate material exposure to carbon-intensive manufacturing or heavy physical assets, which modestly reduces environmental transition risk versus industrial peers.

Social

High R&D spend relative to revenue suggests a workforce centered on specialized scientific talent, which can support peer-relative human-capital quality but also raises retention dependence.

Stock-based compensation at a meaningful revenue share can align employees with long-term value creation, although it may dilute the social advantage versus peers with lower equity reliance.

The available data do not show direct patient-safety, access, or community-impact metrics, limiting confidence that VSTM is socially stronger than comparable biotech peers.

A research-intensive operating model typically concentrates social risk in talent attraction and workplace culture, but the provided metrics do not indicate a peer-leading social profile.

Governance

Stock-based compensation at 11.1% of revenue suggests governance pressure from dilution and incentive design, which is common in biotech but still weighs on peer-relative discipline.

Debt-to-equity of 1.69 indicates moderate balance-sheet leverage, and while not extreme, it leaves governance more exposed than peers with cleaner capital structures.

Net debt to EBITDA is low, which supports financial oversight credibility, but the metric is less informative for a development-stage company than for profitable peers.

The absence of disclosed board, audit, or shareholder-rights metrics prevents evidence of governance strength above the peer median, keeping the score in the moderate range.

Overall Score

VSTM’s ESG profile is broadly in line with development-stage biotech peers, with modest strengths in capital-light operations offset by limited disclosure depth and dilution-related governance pressure.

Score Driver: Limited ESG Disclosure And Only Modest Peer-Relative Differentiation Across The Three Pillars.